Ultragenyx Pharmaceutical(US:RARE) Globenewswire·2026-03-18 21:45Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Ultragenyx Pharmaceutical Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Ultragenyx common stock between August 3, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 6, 2026 [3]. - The lawsuit claims that Ultragenyx provided misleading information regarding the efficacy of setrusumab in reducing fracture rates in Osteogenesis Imperfecta patients, leading to inflated stock prices [5][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in securities class action settlements since 2013 [4]. Group 3: Case Specifics - The lawsuit alleges that Ultragenyx's positive statements about setrusumab's potential were misleading, as the increase in bone density did not correlate with a decrease in fracture rates, contrary to what was claimed [6].